阿托伐他汀治疗原发性高脂血症的效果观察

目的 探讨阿托伐他汀治疗原发性高脂血症的临床效果.方法 选取2012年1月～2013年1月本院收的原发性高脂血症患者150例,将其随机分为观察组和对照组各75例,观察组采用阿托伐他汀治疗,对照组用辛伐他汀治疗,治疗3个月后比较两组的临床疗效,评价两组治疗前后总胆固醇（TC）、三酰甘油（TG）、高度脂蛋白胆固醇（HDL-C）和低密度脂蛋白胆固醇（LDL-C）的变化.结果 治疗3个月后,观察组显效率50.67％,显著高于对照组的38.67％,差异有统计学意义（P＜0.05）;观察组总有效率为88.00％,对照组总有效为84.00％,两组差异无统计学意义（P＞0.05）.两组治疗后TC、TG、LDL-C均较治疗降低,HDL-C较治疗前升高同组治疗前后差异有统计学意义（P＜0.05）;观察组各指标改善幅度优于对照组,两组治疗后差异有统计学意（P＜0.05）.结论 阿托伐他汀治疗原发性高脂血症效果显著,可明显降低TC、TG、LDL-C水平,无严重不良应,值得临床推广应用.

Effect observation of atorvastatin in treatment of primary hyperlipidemia

Objective To investigate the clinical efficacy of atorvastatin in the treatment of primary hyperlipidemia. Methods 150 cases of patients with primary hyperlipidemia in our hospital from January 2012 to January 2013 were selected and randomly divided into observation group and control group,75 cases in the observation group were given atorvastatin therapy,75 cases in the control group were given simvastatin,after 3 months of treatment,the clinical effica- cy were compared between two groups,and the total cholesterol （TC）,triglyceride （TG）,high density lipoprotein choles- terol （HDL-C） and low density lipoprotein cholesterol （LDL-C） changes before and after treatment of two groups were evaluated. Results After 3 months of treatment, the effective rate of the observation group was 50.67%, significantly higher than 38.67% of the control group, the difference was statistically significant （P〈0.05）;the total effective rate of the observation group was 88.00%, that of control group was 84.00%, the difference was not significant （P〉0.05）.After treatment,TC,TG,LDL-C of the two groups were all reduced, HDL-C were increased, compared with that before treat- ment, the difference was statistically significant （P〈0.05）;the improvement of each index in the observation group were better than thoses of the control group, the differences were significant （P〈0.05）.Conclusion The effect of atorvastatin in treatment of primary hypedipidemia is significant, can significantly reduce the TC,TG,LDL-C levels, has no serious adverse reactions, is worthy of clinical application.